BAMBI GRILLEY to Genetic Therapy
This is a "connection" page, showing publications BAMBI GRILLEY has written about Genetic Therapy.
Connection Strength
0.470
-
Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Cytotherapy. 2003; 5(3):197-207.
Score: 0.152
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.128
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.041
-
International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Cytotherapy. 2023 09; 25(9):920-929.
Score: 0.040
-
An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies. Cytotherapy. 2023 07; 25(7):712-717.
Score: 0.039
-
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
Score: 0.038
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.032